Modification Of Immune Cells Research Articles

Precision Gene Editing Strategies with CRISPR-Cas9 for Advancing Cancer Immunotherapy and Alzheimer's Disease

Precision medicine approaches such as gene editing via clustered regularly interspaced short palindromic repeat (CRISPR) and their associated protein (Cas-9) are revolutionizing treatment strategies for complex diseases such as Alzheimer and cancer. In this review, we explore the application of CRISPR-Cas9 in advancing therapies for these conditions, as well as its potential in targeting senescent cells. Since the risk of Alzheimer’s disease is strongly associated with genetic mutations and variations, the use of gene editing technologies to rectify these genetic errors by modifying disease-associated proteins becomes relevant. For cancer, to enhance immunotherapy approaches, modification of immune cells have been utilized to improve their anti-tumor efficacy. Additionally, the review also investigates the role of CRISPR-Cas9 in targeting senescent cells, which are implicated in both aging-related disorders and cancer progression. While challenges remain in introducing delivery methods and specificity, CRISPR-Cas9 represents a significant advancement in developing targeted, personalized treatments for these challenging health issues.

Integrative analysis of bulk and single-cell RNA sequencing data reveals distinct subtypes of MAFLD based on N1-methyladenosine regulator expression

BackgroundMetabolic dysfunction-associated fatty liver disease (MAFLD) is now the most prevalent chronic liver disease worldwide, with an increasing incidence rate. MAFLD is a heterogeneous disease that can have a low or high-risk profile for developing severe liver disease in its natural course. Recent evidence has highlighted the critical role of RNA methylation modification in the pathogenesis of various liver diseases. However, it remains unclear whether the RNA N1-methyladenosine (m1A) modification of immune cells could potentially contribute to the pathogenesis and heterogeneity of MAFLD. Materials and methodsTo address this issue, we conducted an integrated bioinformatics analysis of MAFLD bulk and single-cell RNA sequencing (scRNA-seq) data to pinpoint m1A regulators in the network. This was followed by a description of the immune landscape, pathway enrichment analysis, and molecular subtyping. ResultsThe expression patterns of m1A regulatory genes stratify MAFLD into two molecular subtypes, Cluster 1 and Cluster 2. These subtypes demonstrate different immune cell infiltration with distinct inflammation characteristics, which suggest different immune-inflammatory responses in the liver. Notably, Cluster 2 is associated with pro-inflammation and may be more likely to lead to progressive stages of MAFLD. Through intersection analysis of weighted gene co-expression network analysis (WGCNA) and m1A regulatory genes, three true hub genes (ALKBH1, YTHDC1, and YTHDF3) were identified, all of which were strongly correlated with infiltrating immune cells. The specific signaling pathways involved in the three core genes were derived from genomic variation analysis. Furthermore, scRNA-seq data from 33,168 cells from six liver samples identified 26 cell clusters and eight cell types, with endothelial cells, macrophages, and monocytes showing the most significant differences between MAFLD and normal controls. The cell-cell communication network between immune cells and non-parenchymal cells was extremely sophisticated and changed significantly in MAFLD. ConclusionsIn summary, these findings demonstrate the involvement of m1A in MAFLD heterogeneity and emphasize the crucial role of m1A modulation of immune cells in regulating inflammation in MAFLD. These results may suggest potential therapeutic strategies for MAFLD.

Injectable Scaffolds for In Vivo Programmed Macrophages Manufacture and Postoperative Cancer Immunotherapy

AbstractCancer recurrence and metastasis after surgical resection is a vital reason of treatment failure. The modification of immune cells through implanted biomaterials is a promising postoperative immunotherapy. Herein, an injectable hydrogel scaffold loaded with engineered exosome mimetics that in vivo recruits and programs endogenous macrophages into M1 binding with anti‐CD47 antibody (M1‐aCD47 macrophages) for postoperative cancer immunotherapy is developed. Briefly, M1 macrophages‐derived exosome mimetics co‐modified with vesicular stomatitis virus glycoprotein (VSV‐G) and aCD47 (V‐M1EM‐aCD47) are encapsulated in injectable chitosan hydrogel. Such hydrogel recruits inherent macrophages in situ and releases V‐M1EM‐aCD47 that programs M2 to M1‐aCD47 macrophages. M1‐aCD47 macrophages own dual‐functions of tumor‐homing and enhanced phagocytosis. They can actively target to tumor cells for delivery of aCD47 that blocks the “don't eat me” signal, thereby promoting phagocytosis of macrophages to cancer cells. Furthermore, V‐M1EM‐aCD47 hydrogel implanted into resection site of 4T1 breast tumor inhibits tumor recurrence and metastasis by phagocytosis of M1‐aCD47 macrophages and T cell‐mediated immune responses. The findings demonstrate that biomaterials can be designed in vivo to program inherent macrophages, thereby activating the innate and adaptive immune systems for prevention of postoperative tumor recurrence and metastasis.

Climate change and public health: The effects of global warming on the risk of allergies and autoimmune diseases: The effects of global warming on the risk of allergies and autoimmune diseases.

Global climate change and extreme weather events are associated with epigenetic modifications in immune cells, leading to the possible increased risk and prevalence of allergies and autoimmune diseases.

A Survey on Immune System in Genetic Engineering and their Applications

The increasing number of human diseases has become a major global concern. Researchers have found a novel way to defend against some of the deadliest diseases emerging across the globe. Incorporating a genetic modifications in immune cells can result in producing more powerful antibodies. With this technology, researchers have now successfully defended a potentially fatal lung infection. The similar approach might be effective in treating other human diseases. The integration of immune system in genetic engineering is being studied by combining wide range of techniques and organisms from agriculturally relevant plants to other genetic models such as Drosophila to humans. This initiates the research investigations on the rapid advancement of genetic engineering, including advancements in research and education. This study discusses the concept of genetic engineering in the immune system, as well as various types of genetic engineering and their applications. This work discusses about preserving an endangered species while promoting free market environmentalism.

A Survey on Immune System in Genetic Engineering and their Applications

The increasing number of human diseases has become a major global concern. Researchers have found a novel way to defend against some of the deadliest diseases emerging across the globe. Incorporating a genetic modifications in immune cells can result in producing more powerful antibodies. With this technology, researchers have now successfully defended a potentially fatal lung infection. The similar approach might be effective in treating other human diseases. The integration of immune system in genetic engineering is being studied by combining wide range of techniques and organisms from agriculturally relevant plants to other genetic models such as Drosophila to humans. This initiates the research investigations on the rapid advancement of genetic engineering, including advancements in research and education. This study discusses the concept of genetic engineering in the immune system, as well as various types of genetic engineering and their applications. This work discusses about preserving an endangered species while promoting free market environmentalism.

Cancer Metabolism: The Role of Immune Cells Epigenetic Alteration in Tumorigenesis, Progression, and Metastasis of Glioma.

Glioma is a type of brain and spinal cord tumor that begins in glial cells that support the nervous system neurons functions. Age, radiation exposure, and family background of glioma constitute are risk factors of glioma initiation. Gliomas are categorized on a scale of four grades according to their growth rate. Grades one and two grow slowly, while grades three and four grow faster. Glioblastoma is a grade four gliomas and the deadliest due to its aggressive nature (accelerated proliferation, invasion, and migration). As such, multiple therapeutic approaches are required to improve treatment outcomes. Recently, studies have implicated the significant roles of immune cells in tumorigenesis and the progression of glioma. The energy demands of gliomas alter their microenvironment quality, thereby inducing heterogeneity and plasticity change of stromal and immune cells via the PI3K/AKT/mTOR pathway, which ultimately results in epigenetic modifications that facilitates tumor growth. PI3K is utilized by many intracellular signaling pathways ensuring the proper functioning of the cell. The activation of PI3K/AKT/mTOR regulates the plasma membrane activities, contributing to the phosphorylation reaction necessary for transcription factors activities and oncogenes hyperactivation. The pleiotropic nature of PI3K/AKT/mTOR makes its activity unpredictable during altered cellular functions. Modification of cancer cell microenvironment affects many cell types, including immune cells that are the frontline cells involved in inflammatory cascades caused by cancer cells via high cytokines synthesis. Typically, the evasion of immunosurveillance by gliomas and their resistance to treatment has been attributed to epigenetic reprogramming of immune cells in the tumor microenvironment, which results from cancer metabolism. Hence, it is speculative that impeding cancer metabolism and/or circumventing the epigenetic alteration of immune cell functions in the tumor microenvironment might enhance treatment outcomes. Herein, from an oncological and immunological perspective, this review discusses the underlying pathomechanism of cell-cell interactions enhancing glioma initiation and metabolism activation and tumor microenvironment changes that affect epigenetic modifications in immune cells. Finally, prospects for therapeutic intervention were highlighted.

Lactococcus lactis subsp. cremoris C60 induces macrophages activation that enhances CD4+ T cell-based adaptive immunity.

Lactococcus lactis subsp. cremoris C60 is a probiotic strain that induces diverse functional modifications in immune cells. In this report, as a novel effect of C60 on myeloid lineage cells, we show that C60 enhances the immunological function of macrophages that consequently promotes CD4+ T cell activity in an antigen-dependent manner. Heat-killed (HK) C60 induced the production of pro-inflammatory cytokines in thioglycolate-elicited peritoneal macrophages (TPMs) much stronger than Toll-like receptor (TLR) ligand stimulation. The HK-C60 treatment also augmented the expression of antigen-presenting and co-stimulatory molecules, such as major histocompatibility complex (MHC) class II, CD80, and CD86, as well as antigen uptake in TPMs. These HK-C60-mediated functional upregulations in TPMs resulted in the promotion of CD4+ T cell activation in an antigen-dependent manner. Interestingly, the TPMs that originated from the mice fed the HK-C60 diet showed pre-activated characteristics, which was confirmed by the upregulation of cytokine production and antigen presentation-related molecule expression under lipopolysaccharide (LPS) stimulation. Furthermore, the antigen-dependent CD4+ T cell activation was also enhanced by the TPMs. This implied that antigen presentation activity was enhanced in the TPMs that originated from the HK-C60 diet mice. Thus, C60 effectively upregulates the immunological function of macrophages that directly connects to CD4+ T cell-based adaptive immunity.

Integrated analyses of m1A regulator-mediated modification patterns in tumor microenvironment-infiltrating immune cells in colon cancer

ABSTRACT Emerging evidence has revealed the crucial role of transcriptional RNA methyladenosine modification in immune response. However, the potential role of RNA N1-methyladenosine (m1A) modification of immune cells in the tumor microenvironment (TME) still remains unclear. In this study, we identified three distinct m1A modification patterns based on the integrated analyses of nine m1A regulators, which are significantly related to Relapse-free survival (RFS), Overall survival (OS), and TME infiltration cells in colon cancer patients. Furthermore, the m1AScore was generated by using principal components analysis (PCA) of expression of the 71 m1A-related genes to further demonstrate the characteristics of m1A patterns in colon cancer. In summary, a low m1AScore could be characterized by lower EMT, pan-F TBRS, and TNM stages, as well as less presence of lymphatic invasion, and, hence, good prognosis. At the same time, a low m1AScore could also be linked to CD8 + T effector proliferation, in addition to high microsatellite instability (MSI), neoantigen burden and PD-L1 expression, showing prolonged survival and better response after undergoing an anti-PD-L1 immunotherapy regimen in the public immunotherapy cohort. Our work reveals that m1A modification patterns play a key role in the formation of TME complexity and diversity in the context of immune cell infiltration. Accordingly, this m1AScore system provides an efficient method by which to identify and characterize TME immune cell infiltration, thereby allowing for more personalized and effective antitumor immunotherapy strategies.

The Epigenetics of Lupus Erythematosus.

Systemic lupus erythematosus (SLE) is a life-threatening autoimmune disease that is characterized by dysregulated dendritic cells, T and B cells, and abundant autoantibodies. The pathogenesis of lupus remains unclear. However, increasing evidence has shown that environment factors, genetic susceptibilities, and epigenetic regulation contribute to abnormalities in the immune system. In the past decades, several risk gene loci have been identified, such as MHC and C1q. However, genetics cannot explain the high discordance of lupus incidence in homozygous twins. Environmental factor-induced epigenetic modifications on immune cells may provide some insight. Epigenetics refers to inheritable changes in a chromosome without altering DNA sequence. The primary mechanisms of epigenetics include DNA methylation, histone modifications, and non-coding RNA regulations. Increasing evidence has shown the importance of dysregulated epigenetic modifications in immune cells in pathogenesis of lupus, and has identified epigenetic changes as potential biomarkers and therapeutic targets. Environmental factors, such as drugs, diet, and pollution, may also be the triggers of epigenetic changes. Therefore, this chapter will summarize the up-to-date progress on epigenetics regulation in lupus, in order to broaden our understanding of lupus and discuss the potential roles of epigenetic regulations for clinical applications.

Targeting tumour associated antigens expressed in osteosarcoma and ewing's sarcoma with CAR-T cells

Background & Aim The establishment of Chimeric Antigen Receptor (CAR) T cell immunotherapy as a treatment for refractory and relapsed B cell malignancies demonstrates that genetic modification of immune cells to circumvent tumour cell immune escape is a powerful strategy to pursue in the context of other paediatric cancers. However, efforts to develop effective CAR T cell therapies for solid tumours face a number of challenges; establishing an effective dose, route of administration, tumour cell mediated dampening of immune cell function, and overcoming heterogeneous antigen expression across the tumour cell population. The focus of our work is to translate the therapeutic potential of CAR-T cell therapy into an effective treatment for children with recurrent or refractory bone tumours. In addition, we are seeking to ensure effective targeting of metastatic spread of these tumours, since metastasis at the time of diagnosis is a significant problem in this patient population. Methods, Results & Conclusion We have developed reagents and methodology to generate CAR T cells specific for the protein Erythropoietin-producing Hepatocellular receptor tyrosine kinase class A2 (EphA2), which is expressed on a range of paediatric solid tumours. We can show that EphA2 CAR T cells specifically target and kill EphA2+ osteosarcoma and Ewing's sarcoma cell lines in vitro, alongside secretion of cytokines indicative of effector T cell activation. In in vivo sub-cutaneous osteosarcoma and Ewing's sarcoma xenograft models, EphA2 CAR T cells effectively mediate complete tumour regression in a dose and route dependent manner, with direct injection into established tumours resulting in extended survival. Systemic delivery of CAR T cells was also effective at mediating tumour regression and extending survival, but required a higher cell dose. Studies testing EphA2 CAR T cell efficacy against metastatic osteosarcoma deposits are currently ongoing. Further work focussing on safety and possible off-target effects, design of alternative gene therapy vectors and combinatorial testing of EphA2 CAR T cells with CAR T cells targeting alternative antigens, or immune checkpoint blockade, will elucidate a way forward in designing an effective CAR T cell therapy for osteosarcoma and Ewing's sarcoma.

Beneficial effects of Brazilian propolis on type 2 diabetes in ob/ob mice

The anti-diabetic effects of Brazilian propolis were examined using ob/ob mice. Although repeated injection of an ethanol extract of Brazilian propolis (100 mg/kg, ip, twice a week for 12 weeks) did not affect body weight gain and food intake of ob/ob mice, blood glucose and plasma cholesterol levels were significantly attenuated. Moreover, the propolis extract partially restored glucose tolerance and insulin resistance, indicating anti-diabetic properties of the extract. The propolis-treated mice exhibited lower weight gain in mesenteric adipose tissue, while weight gains in inguinal and epididymal adipose tissues were not modulated. Flow cytometric and microscopic analyses suggested that the extract promoted accumulation of eosinophils into mesenteric and epididymal adipose tissues. Alternatively, the ratio of M1-like macrophages to M2-like macrophages in mesenteric adipose tissue was reduced by the propolis injection, coincident with the decrement of the number of interleukin-12A+ cells. Levels of M1 macrophage markers, such as Itgax and Il12b transcripts, were decreased in the vascular stromal fraction of mesenteric adipose tissue, whereas those of pan-macrophage markers Emr1 and Cd68 were not influenced. Microarray and subsequent gene ontology term analyses suggested that propolis attenuated immune activation in mesenteric adipose tissues. Taken together, this indicates that Brazilian propolis improves diabetes in ob/ob mice, presumably through modification of immune cells in mesenteric adipose tissues.

The Use of Gene Therapy Tools in Reproductive Immunology Research

Mammalian pregnancy is a complex phenomenon allowing the maternal immune system to support its allogeneic fetus, while still being effective against pathogens. Gene therapy approaches have the potential to treat devastating inherited diseases for which there is a little hope of finding a conventional cure. In reproductive medicine, experimental trials have been made so far only for correcting gene defects in utero. The use of gene therapy for improving pregnancy-rate success or avoiding pregnancy-related diseases i.e. miscarriage or pre-eclampsia, remains a very distant goal with unresolved moral and ethical aspects. However, gene therapy may help determining the role of several genes in supporting fetal growth and/or avoiding its rejection experimentally and might further help to identify new targets of intervention. Gene therapy strategies to avoid fetal rejection may include the transfer and expression of cyto-protective molecules locally at the fetal-placental interface. In addition, the ex-vivo genetic modification of immune cells for tolerance induction is a novel and tempting approach. In this regard, we have confirmed the role of the cyto-protective and immunomodulatory molecule Heme Oxygenase-1 (HO-1), by treating animals undergoing abortion with an adenovirus coding for HO-1. Since the sole application of a control vector did not provoke deleterious effects in pregnancy outcome, we propose the use of experimental gene therapy for unveiling molecular and cellular pathways leading to pregnancy success.